Jiang Zhong Pharmaceutical Co Ltd banner

Jiang Zhong Pharmaceutical Co Ltd
SSE:600750

Watchlist Manager
Jiang Zhong Pharmaceutical Co Ltd Logo
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
Watchlist
Price: 23.92 CNY -0.25% Market Closed
Market Cap: ¥15.2B

P/B

3.8
Current
6%
More Expensive
vs 3-y average of 3.6

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
3.8
=
Market Cap
¥15.8B
/
Total Equity
¥4B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
3.8
=
Market Cap
¥15.8B
/
Total Equity
¥4B

Valuation Scenarios

Jiang Zhong Pharmaceutical Co Ltd is trading above its 3-year average

If P/B returns to its 3-Year Average (3.6), the stock would be worth ¥22.52 (6% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-36%
Maximum Upside
No Upside Scenarios
Average Downside
22%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 3.8 ¥23.92
0%
3-Year Average 3.6 ¥22.52
-6%
5-Year Average 3.4 ¥21.59
-10%
Industry Average 2.4 ¥15.24
-36%
Country Average 2.4 ¥15.51
-35%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
CN
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
15.2B CNY 3.8 16.7
US
Eli Lilly and Co
NYSE:LLY
883B USD 33.3 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 6.8 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 6.1 27.8
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.1 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 7.3 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 6.2 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 1.8 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 6.6 17.3
P/E Multiple
Earnings Growth PEG
CN
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
Average P/E: 21.8
16.7
11%
1.5
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.8
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

In line with most companies in China
Percentile
69th
Based on 7 605 companies
69th percentile
3.8
Low
0 — 1.5
Typical Range
1.5 — 3.9
High
3.9 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.4
70th Percentile 3.9
Max 1 172 445.9

Jiang Zhong Pharmaceutical Co Ltd
Glance View

Market Cap
15.2B CNY
Industry
Pharmaceuticals

Jiang Zhong Pharmaceutical Co Ltd. has etched its mark in the bustling landscape of China's pharmaceutical industry by embracing a strategic blend of traditional Chinese medicine (TCM) and modern medical practices. Founded in 1969 and headquartered in Wuhan, this company has steadily navigated the dynamic tides of China's healthcare sector. Jiang Zhong specializes in producing and marketing a wide array of TCM products, which are deeply rooted in ancient Chinese medical philosophies and practices. These offerings cater to various health needs, including gastrointestinal management, respiratory treatments, and nutritional supplements, which resonate well with China's rich cultural heritage of natural health solutions. The company's commitment to quality and efficacy has allowed it to carve out a substantial market niche where tradition meets innovation. Making money for Jiang Zhong Pharmaceutical Co Ltd. revolves around its robust distribution networks and strong brand presence across key domestic markets. The company has invested in extensive research and development initiatives to ensure its product line remains relevant and effective in addressing modern health challenges, alongside its traditional product offerings. By leveraging a diverse marketing strategy that includes partnerships with healthcare institutions, direct consumer promotions, and digital platforms, Jiang Zhong successfully taps into both local and international markets. Additionally, the company enhances its profitability through economies of scale and strategic cost management, allowing it to maintain competitive pricing while achieving substantial revenue growth. This balanced approach of blending tradition with innovation continues to fortify Jiang Zhong Pharmaceutical's position as a respected entity in both TCM and broader pharmaceutical realms.

Intrinsic Value
27.76 CNY
Undervaluation 14%
Intrinsic Value
Price ¥23.92
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett